PATENT CLAIM ANALYSIS

Application Number: 15742458
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "401000"]

Abstract:
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. Also included herein are methods for extending lifespan.

Claim (Index 37):
The method of any one of  claims 1 - 36 , wherein the compound is selected from an MDM2 inhibitor; an inhibitor of one or more BCL-2 anti-apoptotic protein family members wherein the inhibitor inhibits at least BCL-xL; an Akt specific inhibitor; an inhibitor of Akt 1, 2, or 3; a c-Jun N-terminal kinase (JNK)1, JNK2, JNK3, or Kit inhibitor; a protein phosphatase 2C (PP2C) or MAP kinase phosphatase-1 (MKP-1) inhibitor; a reactive oxygen species (ROS) inducer; an S6 kinase inhibitor; a protein kinase A (PKA) inhibitor; an inhibitor of a checkpoint kinase (Chk)1 or checkpoint kinase 2; an inhibitor of platelet-derived growth factor receptor beta (PDGFRB); an inhibitor of vascular endothelial growth factor receptor (VEGFR)-2; an inhibitor of phosphoinositide 3-kinase (PI3K); an inhibitor of apoptosis signal-regulating kinase 1 (ASK1); an inhibitor of spleen tyrosine kinase (Syk); an inhibitor of epidermal growth factor receptor (EGFR); an inhibitor of cathepsin; a glucosamine analog; an inhibitor of poly ADP ribose polymerase (PARP)1 or PARP2; an inhibitor of Cathepsin H; an inhibitor of cellular FADD-like IL-1\u03b2-converting enzyme-inhibitory protein (c-FLIP); an inhibitor of Serpin; an inhibitor of Ubiquilin-2; an inhibitor of Epiregulin; an inhibitor of Sorting nexin-3 (Snx3); an inhibitor of forkhead box protein O4 (FOXO4); and an inhibitor of Proto-oncogene tyrosine protein kinase Src (Src).

Metadata:
- Claim Count in Document: 26.0
- Percentile: 86.0
- Lexical Diversity: 1.63462
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15455684', '15827539', '15647688', '15114762', '15467129']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8796742586642285
- 35 USC 102 Novelty (BERT): 0.6071752675932499
- Combined Prediction Score: 0.8524243595571307
- Mean Citation Score: 648.2822719999998
- Max Citation Score: 688.408
- Similarity Product: 458.30805470561984

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test